T-cell prolymphocytic leukemia
GPTKB entity
Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:healthcare_organization
|
| gptkbp:affects |
T-cells
|
| gptkbp:associated_with |
infections
chromosomal abnormalities autoimmune disorders secondary malignancies |
| gptkbp:clinical_trial |
gptkb:fandom
ongoing thrombocytopenia lymphocytosis high white blood cell count hyperleukocytosis |
| gptkbp:current_use |
gptkb:healthcare_organization
|
| gptkbp:first_described_by |
gptkb:1980s
|
| gptkbp:genetic_diversity |
NOTC H1 mutations
T P53 mutations CDK N2 A deletions TCR gene rearrangements |
| https://www.w3.org/2000/01/rdf-schema#label |
T-cell prolymphocytic leukemia
|
| gptkbp:is_a |
hematological malignancy
|
| gptkbp:is_popular_in |
rare
|
| gptkbp:occurs_in |
adults
|
| gptkbp:research_focus |
biomarkers
genetic mutations new therapies |
| gptkbp:risk_factor |
age
gender viral infections exposure to chemicals |
| gptkbp:social_responsibility |
variable
blood tests cytogenetic analysis bone marrow biopsy immunophenotyping |
| gptkbp:symptoms |
fatigue
weight loss fever night sweats lymphadenopathy splenomegaly |
| gptkbp:treatment |
gptkb:vaccine
gptkb:drug palliative care clinical trials combination therapy supportive care monoclonal antibodies radiation therapy chemotherapy targeted therapy follow-up care symptom management relapse clinical management remission stem cell transplant antibody therapy |